The trajectory of copyright's flagship drug presents a nuanced case for stakeholders in the drug sector. While initially a phenomenal success, producing huge profits, the exclusivity lapse and the subsequent flood of cheaper alternatives have drastically affected earnings. This presents questions about the ongoing profitability of analogous medi… Read More